Ketamine modulates calcium homeostasis in hypoxia-reoxygenated cardiomyocytes

Tissue Engineering and Regenerative Medicine

Volumn 5, Issue 3, 2008, Pages 512-520

  Roh, Jang Ho ^a   Chang, Woochul ^a   Lim, Soyeon ^a   Song, Heesang ^b   Song, Byeong Wook ^a   Kim, Hye Jung ^a   Cha, Min Ji ^a   Jang, Yangsoo ^a   Chung, Nam Sik ^a   Hong, Yong Woo ^c   Hwang, Ki Chul ^a  

^a Yonsei University College of Medicine   (South Korea)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Ajou University School of Medicine   (South Korea)

Author keywords

Calcium homeostasis; Cardiomyocytes; Hypoxia reoxygenation; Ketamine

Indexed keywords

ANTI-APOPTOTIC PROTEIN; CALCIUM HOMEOSTASIS; CARDIOMYOCYTES; CRITICALLY-ILL PATIENTS; HYPOXIA-REOXYGENATION; ISCHEMIA-REPERFUSION INJURY; KETAMINE; MYOCARDIAL PROTECTION;

ANESTHETICS; CALCIUM; CALMODULIN; PHYSIOLOGY;

AMINES;

EID: 84884546515     PISSN: 17382696     EISSN: 22125469     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. SM Green, NE Johnson, Ketamine sedation for pediatric procedures: Part 2, Review and implications, Ann Emerg Med, 19, 1033 (1990).
2. M Shimoyama, N Shimoyama, AL Gorman, et al., Oral ketamine is antinociceptive in the rat formalin test: role of the metabolite, norketamine, Pain, 81, 85 (1999).
3. Y Yanagihara, S Kariya, M Ohtani, et al., Involvement of CYP2B6 in n-demethylation of ketamine in human liver microsomes, Drug Metab Dispos, 29, 887 (2001).
4. Y Hijazi, R Boulieu, Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes, Drug Metab Dispos, 30, 853 (2002).
5. DL Reich, G Silvay, Ketamine: an update on the first twentyfive years of clinical experience, Can J Anaesth, 36, 186 (1989).
6. B Swynghedauw, Molecular mechanisms of myocardial remodeling, Physiol Rev, 79, 215 (1999).
7. E Mirit, C Gross, Y Hasin, et al., Changes in cardiac mechanics with heat acclimation: adrenergic signaling and SR-Ca regulatory proteins, Am J Physiol Regul Integr Comp Physiol, 279, R77 (2000).
8. 2+ cycling after left ventricular assist device support in the failing human heart, J Am Coll Cardiol, 44, 837 (2004).
9. JC Drummond, MAC for halothane, enflurane, and isoflurane in the New Zealand white rabbit: and a test for the validity of MAC determinations, Anesthesiology, 62, 336 (1985).
10. Y Hamaya, T Takeda, S Dohi, et al., The effects of pentobarbital, isoflurane, and propofol on immediate-early gene expression in the vital organs of the rat, Anesth Analg, 90, 1177 (2000).
11. S Huke, LH Liu, D Biniakiewicz, et al., Altered force-frequency response in non-failing hearts with decreased SERCA pumplevel, Cardiovasc Res, 59, 668 (2003).
12. CM Terracciano, J Hardy, EJ Birks, et al., Clinical recovery from end-stage heart failure using left-ventricular assist device and pharmacological therapy correlates with increased sarcoplasmic reticulum calcium content but not with regression of cellular hypertrophy, Circulation, 109, 2263 (2004).
13. 2+-ATPase and alpha-myosin heavy chain in rat hearts, J Clin Invest, 100, 1742 (1997).
14. rd, Simultaneous evaluation of left ventricular end-systolic pressure-volume ratio and time constant of isovolumic pressure decline in dogs exposed to equivalent MAC halothane and isoflurane, Anesthesiology, 68, 764 (1988).
15. KC Hwang, S Lim, HM Kwon, et al., Phospholipase C-delta1 rescues intracellular Ca2+ overload in ischemic heart and hypoxic neonatal cardiomyocytes, J Steroid Biochem Mol Biol, 91, 131 (2004).
16. DL Downie, NP Franks, WR Lieb, Effects of thiopental and its optical isomers on nicotinic acetylcholine receptors, Anesthesiology, 93, 774 (2000).
17. 2+)-release channels, Trends Pharmacol Sci, 15, 145 (1994).
18. A Molojavyi, B Preckel, T Comfere, et al., Effects of ketamine and its isomers on ischemic preconditioning in the isolated rat heart, Anesthesiology, 94, 623 (2001).
19. JL Hanouz, L Zhu, E Persehaye, et al., Ketamine preconditions isolated human right atrial myocardium: roles of adenosine triphosphate-sensitive potassium channels and adrenoceptors, Anesthesiology, 102, 1190 (2005).
20. Z Sheng, K Knowlton, J Chen, et al., Cardiotrophin 1 (CT-1) inhibition of cardiac myocyte apoptosis via a mitogen-activated protein kinase-dependent pathway. Divergence from downstream CT-1 signals for myocardial cell hypertrophy, J Biol Chem, 272, 5783 (1997).
21. G Kulik, A Klippel, MJ Weber, Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt, Mol Cell Biol, 17, 1595 (1997).
22. Y Sato, DG Ferguson, H Sako, et al., Cardiac-specific overexpression of mouse cardiac calsequestrin is associated with depressed cardiovascular function and hypertrophy in transgenic mice, J Biol Chem, 273, 28470 (1998).
23. AG Schmidt, VJ Kadambi, N Ball, et al., Cardiac-specific overexpression of calsequestrin results in left ventricular hypertrophy, depressed force-frequency relation and pulsus alternans in vivo, J Mol Cell Cardiol, 32, 1735 (2000).
24. 2+ disturbances, and cell death in renal epithelial cells, J Biol Chem, 272, 21751 (1997).
25. 2+ increases and cell death, J Biol Chem, 273, 12858 (1998).
26. KM Lawrence, A Chanalaris, T Scarabelli, et al., K(ATP) channel gene expression is induced by urocortin and mediates its cardioprotective effect, Circulaion, 106, 1556 (2002).
27. 2+ pump (PMCA) isoforms in the gerbil brain: effect of ischemia-reperfusion injury, Neurochem Int, 35, 221 (1999).
28. SR Houser, V Piacentino 3rd, J Weisser, Abnormalities of calcium cycling in the hypertrophied and failing heart, J Mol Cell Cardiol, 32, 1595 (2000).